PureTech Health Launches Celea Therapeutics to Deliver Respiratory Diseases Therapies

MT Newswires Live

Aug 12, 2025

PureTech Health (PRTC) said Tuesday it has launched Celea Therapeutics, a company focused on developing therapies for respiratory diseases.

Sven Dethlefs, who led PureTech's deupirfenidone program for more than a year, was appointed to lead Celea.

Celea's lead program, deupirfenidone or LYT-100, is a phase 3-ready candidate initially being developed for the treatment of idiopathic pulmonary fibrosis, a lung disease. PureTech said the drug also shows potential in other fibrotic and inflammatory lung conditions.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2558864144"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2558864144\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2558864144?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-12 19:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2558864144","market":"hk","top_or_hot":-1,"title":"PureTech Health Launches Celea Therapeutics to Deliver Respiratory Diseases Therapies","media":"MT Newswires Live","content":"<html><body><p> PureTech Health (PRTC) said Tuesday it has launched Celea <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, a company focused on developing therapies for respiratory diseases.</p><p>Sven Dethlefs, who led PureTech's deupirfenidone program for more than a year, was appointed to lead Celea.</p><p>Celea's lead program, deupirfenidone or LYT-100, is a phase 3-ready candidate initially being developed for the treatment of idiopathic pulmonary fibrosis, a lung disease. PureTech said the drug also shows potential in other fibrotic and inflammatory lung conditions.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PureTech Health Launches Celea Therapeutics to Deliver Respiratory Diseases Therapies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPureTech Health Launches Celea Therapeutics to Deliver Respiratory Diseases Therapies\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-08-12 19:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> PureTech Health (PRTC) said Tuesday it has launched Celea <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, a company focused on developing therapies for respiratory diseases.</p><p>Sven Dethlefs, who led PureTech's deupirfenidone program for more than a year, was appointed to lead Celea.</p><p>Celea's lead program, deupirfenidone or LYT-100, is a phase 3-ready candidate initially being developed for the treatment of idiopathic pulmonary fibrosis, a lung disease. PureTech said the drug also shows potential in other fibrotic and inflammatory lung conditions.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PRTC","symbol_name":"PureTech Health PLC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2558864144","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2558864144","pubTimestamp":1754998883,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"PureTech Health  said Tuesday it has launched Celea Therapeutics, a company focused on developing therapies for respiratory diseases.Sven Dethlefs, who led PureTech's deupirfenidone program for more than a year, was appointed to lead Celea.Celea's lead program, deupirfenidone or LYT-100, is a phase 3-ready candidate initially being developed for the treatment of idiopathic pulmonary fibrosis, a lung disease. PureTech said the drug also shows potential in other fibrotic and inflammatory lung conditions.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PRTC":"PureTech Health PLC","BK4539":"次新股","BK4139":"生物科技","LENZ":"Therapeutics","BK4007":"制药"},"translate_title":"PureTech Health推出Celea Therapeutics提供呼吸道疾病病疗法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRTC":0.9,"LENZ":1},"content_text":"PureTech Health (PRTC) said Tuesday it has launched Celea Therapeutics, a company focused on developing therapies for respiratory diseases.Sven Dethlefs, who led PureTech's deupirfenidone program for more than a year, was appointed to lead Celea.Celea's lead program, deupirfenidone or LYT-100, is a phase 3-ready candidate initially being developed for the treatment of idiopathic pulmonary fibrosis, a lung disease. PureTech said the drug also shows potential in other fibrotic and inflammatory lung conditions.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}